BRAF and neoplasm: Although we showed that PNA-PCR can detect more KRAS mutated cases and that the discrepancy might be due to cases showing a mutation in the primary tumor and not in plasma, and this fact is in agreement with other recent studies which addressed the same question [29,30], further optimization of this methods also might increase the concordance between tumor and plasma as the investigation of KRAS and BRAF mutations consistence in tumor tissue and cfDNA [31].